Literature DB >> 33412555

Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I: Epidemiology, Classification, Diagnosis, Prognosis, Fertility Preservation, and Treatment Recommendations for Localized Stages.

Sabine Kliesch1, Stefanie Schmidt2, Doris Wilborn2, Clemens Aigner3, Walter Albrecht4, Jens Bedke5, Matthias Beintker6, Dirk Beyersdorff7, Carsten Bokemeyer8, Jonas Busch9, Johannes Classen10, Maike de Wit11, Klaus-Peter Dieckmann12, Thorsten Diemer13, Anette Dieing14, Matthias Gockel15, Bernt Göckel-Beining16, Oliver W Hakenberg17, Axel Heidenreich18, Julia Heinzelbecker19, Kathleen Herkommer20, Thomas Hermanns21, Sascha Kaufmann22, Marko Kornmann23, Jörg Kotzerke24, Susanne Krege25, Glen Kristiansen26, Anja Lorch27, Arndt-Christian Müller22, Karin Oechsle8, Timur Ohloff28, Christoph Oing8, Ulrich Otto29, David Pfister18, Renate Pichler30, Heinrich Recken31, Oliver Rick32, Yvonne Rudolph33, Christian Ruf34, Joachim Schirren35, Hans Schmelz36, Heinz Schmidberger37, Mark Schrader38, Stefan Schweyer39, Stefanie Seeling40, Rainer Souchon22, Christian Winter41, Christian Wittekind42, Friedemann Zengerling43, Dirk-Henrik Zermann44, Roger Zillmann45, Peter Albers27.   

Abstract

INTRODUCTION: This is the first German evidence- and consensus-based clinical guideline on diagnosis, treatment, and follow-up on germ cell tumours (GCTs) of the testis in adult patients. We present the guideline content in two publications. Part I covers the topic's background, methods, epidemiology, classification systems, diagnostics, prognosis, and treatment recommendations for the localized stages.
METHODS: An interdisciplinary panel of 42 experts including 1 patient representative developed the guideline content. Clinical recommendations and statements were based on scientific evidence and expert consensus. For this purpose, evidence tables for several review questions, which were based on systematic literature searches (last search was in March 2018) were provided. Thirty-one experts entitled to vote, rated the final clinical recommendations and statements.
RESULTS: We provide 161 clinical recommendations and statements. We present information on the quality of cancer care and epidemiology and give recommendations for staging and classification as well as for diagnostic procedures. The diagnostic recommendations encompass measures for assessing the primary tumour as well as procedures for the detection of metastases. One chapter addresses prognostic factors. In part I, we separately present the treatment recommendations for germ cell neoplasia in situ, and the organ-confined stages (clinical stage I) of both seminoma and nonseminoma.
CONCLUSION: Although GCT is a rare tumour entity with excellent survival rates for the localized stages, its management requires an interdisciplinary approach, including several clinical experts. Quality of care is highly related to institutional expertise and can be reassured by established online-based second-opinion boards. There are very few studies on diagnostics with good level of evidence. Treatment of metastatic GCTs must be tailored to the risk according to the International Germ Cell Cancer Collaboration Group classification after careful diagnostic evaluation. An interdisciplinary approach as well as the referral of selected patients to centres with proven experience can help achieve favourable clinical outcomes.
© 2021 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Clinical practice guideline; Diagnosis; Fertility preservation; Germ cell tumour of the testis; Prognosis; Staging

Mesh:

Year:  2021        PMID: 33412555      PMCID: PMC8006579          DOI: 10.1159/000510407

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  28 in total

Review 1.  Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion.

Authors:  Christine Chevreau; Catherine Mazerolles; Michel Soulié; Marie-Hélène Gaspard; Loïc Mourey; Louis Bujan; Pierre Plante; Pascal Rischmann; Jean-Marc Bachaud; Bernard Malavaud
Journal:  Eur Urol       Date:  2004-08       Impact factor: 20.096

Review 2.  AGREE II: advancing guideline development, reporting and evaluation in health care.

Authors:  Melissa C Brouwers; Michelle E Kho; George P Browman; Jako S Burgers; Francoise Cluzeau; Gene Feder; Béatrice Fervers; Ian D Graham; Jeremy Grimshaw; Steven E Hanna; Peter Littlejohns; Julie Makarski; Louise Zitzelsberger
Journal:  CMAJ       Date:  2010-07-05       Impact factor: 8.262

3.  Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors.

Authors:  C Albany; N Adra; A C Snavely; C Cary; T A Masterson; R S Foster; K Kesler; T M Ulbright; L Cheng; M Chovanec; F Taza; K Ku; M J Brames; N H Hanna; L H Einhorn
Journal:  Ann Oncol       Date:  2018-02-01       Impact factor: 32.976

4.  Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience.

Authors:  Jeremy F Sturgeon; Malcolm J Moore; David M Kakiashvili; Ignacio Duran; Lynn C Anson-Cartwright; Dominik R Berthold; Padraig R Warde; Mary K Gospodarowicz; Ruth E Alison; Justin Liu; Clement Ma; Greg R Pond; Michael A Jewett
Journal:  Eur Urol       Date:  2010-12-22       Impact factor: 20.096

5.  Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance.

Authors:  Christian Kollmannsberger; Torgrim Tandstad; Philippe L Bedard; Gabriella Cohn-Cedermark; Peter W Chung; Michael A Jewett; Tom Powles; Padraig R Warde; Siamak Daneshmand; Andrew Protheroe; Scott Tyldesley; Peter C Black; Kim Chi; Alan I So; Malcom J Moore; Craig R Nichols
Journal:  J Clin Oncol       Date:  2014-08-18       Impact factor: 44.544

6.  Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.

Authors:  Peter Albers; Roswitha Siener; Susanne Krege; Hans-Uwe Schmelz; Klaus-Peter Dieckmann; Axel Heidenreich; Peter Kwasny; Maik Pechoel; Jan Lehmann; Sabine Kliesch; Kai-Uwe Köhrmann; Rolf Fimmers; Lothar Weissbach; Volker Loy; Christian Wittekind; Michael Hartmann
Journal:  J Clin Oncol       Date:  2008-05-05       Impact factor: 44.544

7.  Changes in epidemiologic features of testicular germ cell cancer: age at diagnosis and relative frequency of seminoma are constantly and significantly increasing.

Authors:  Christian G Ruf; Hendrik Isbarn; Walter Wagner; Margit Fisch; Cord Matthies; Klaus-Peter Dieckmann
Journal:  Urol Oncol       Date:  2013-02-06       Impact factor: 3.498

8.  Bilateral testicular germ cell tumors in patients treated for clinical stage I non-seminoma within two risk-adapted SWENOTECA protocols.

Authors:  Torgrim Tandstad; Arne Solberg; Ulf Håkansson; Olof Stahl; Hege Sagstuen Haugnes; Jan Oldenburg; Olav Dahl; Anders Kjellman; Anders Angelsen; Gabriella Cohn-Cedermark
Journal:  Acta Oncol       Date:  2014-09-05       Impact factor: 4.089

9.  Primary chemotherapy in patients with nonseminomatous germ cell tumors of the testis and biological disease only after orchiectomy.

Authors:  S Culine; C Theodore; M J Terrier-Lacombe; J P Droz
Journal:  J Urol       Date:  1996-04       Impact factor: 7.450

10.  QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies.

Authors:  Penny F Whiting; Anne W S Rutjes; Marie E Westwood; Susan Mallett; Jonathan J Deeks; Johannes B Reitsma; Mariska M G Leeflang; Jonathan A C Sterne; Patrick M M Bossuyt
Journal:  Ann Intern Med       Date:  2011-10-18       Impact factor: 25.391

View more
  9 in total

Review 1.  Management of Germ Cell Tumours of the Testes in Adult Patients: German Clinical Practice Guideline, PART II - Recommendations for the Treatment of Advanced, Recurrent, and Refractory Disease and Extragonadal and Sex Cord/Stromal Tumours and for the Management of Follow-Up, Toxicity, Quality of Life, Palliative Care, and Supportive Therapy.

Authors:  Sabine Kliesch; Stefanie Schmidt; Doris Wilborn; Clemens Aigner; Walter Albrecht; Jens Bedke; Matthias Beintker; Dirk Beyersdorff; Carsten Bokemeyer; Jonas Busch; Johannes Classen; Maike de Wit; Klaus-Peter Dieckmann; Thorsten Diemer; Anette Dieing; Matthias Gockel; Bernt Göckel-Beining; Oliver W Hakenberg; Axel Heidenreich; Julia Heinzelbecker; Kathleen Herkommer; Thomas Hermanns; Sascha Kaufmann; Marko Kornmann; Jörg Kotzerke; Susanne Krege; Glen Kristiansen; Anja Lorch; Arndt-Christian Müller; Karin Oechsle; Timur Ohloff; Christoph Oing; Ulrich Otto; David Pfister; Renate Pichler; Heinrich Recken; Oliver Rick; Yvonne Rudolph; Christian Ruf; Joachim Schirren; Hans Schmelz; Heinz Schmidberger; Mark Schrader; Stefan Schweyer; Stefanie Seeling; Rainer Souchon; Christian Winter; Christian Wittekind; Friedemann Zengerling; D H Zermann; Roger Zillmann; Peter Albers
Journal:  Urol Int       Date:  2021-01-22       Impact factor: 2.089

2.  How to classify, diagnose, treat and follow-up extragonadal germ cell tumors? A systematic review of available evidence.

Authors:  Stefanie Schmidt; Carsten Bokemeyer; Christian Winter; Friedemann Zengerling; Jonas Busch; Julia Heinzelbecker; David Pfister; Christian Ruf; Julia Lackner; Peter Albers; Sabine Kliesch
Journal:  World J Urol       Date:  2022-05-12       Impact factor: 4.226

3.  Prognostic factors in patients with clinical stage I nonseminoma-beyond lymphovascular invasion: a systematic review.

Authors:  Friedemann Zengerling; Dirk Beyersdorff; Jonas Busch; Julia Heinzelbecker; David Pfister; Christian Ruf; Christian Winter; Peter Albers; Sabine Kliesch; Stefanie Schmidt
Journal:  World J Urol       Date:  2022-07-29       Impact factor: 3.661

4.  Testicular germ cell tumours' clinical stage I: comparison of surveillance with adjuvant treatment strategies regarding recurrence rates and overall survival-a systematic review.

Authors:  Christian G Ruf; Stefanie Schmidt; Sabine Kliesch; Christoph Oing; David Pfister; Jonas Busch; Julia Heinzelbecker; Christian Winter; Friedemann Zengerling; Peter Albers; Karin Oechsle; Susanne Krege; Julia Lackner; Klaus-Peter Dieckmann
Journal:  World J Urol       Date:  2022-09-15       Impact factor: 3.661

5.  Effects of epidemiological risk factors on prognosis in testicular cancer.

Authors:  Aykut Demirci; Halil Başar
Journal:  Int Urol Nephrol       Date:  2022-09-14       Impact factor: 2.266

6.  Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study.

Authors:  Klaus-Peter Dieckmann; Tomas Pokrivcak; Lajos Geczi; David Niehaus; Inken Dralle-Filiz; Cord Matthies; Tamas Dienes; Stefanie Zschäbitz; Pia Paffenholz; Tanja Gschliesser; Renate Pichler; Michal Mego; Pia Bader; Friedemann Zengerling; Julia Heinzelbecker; Philipp Krausewitz; Susanne Krege; Gaetano Aurilio; Cem Aksoy; Marcus Hentrich; Christoph Seidel; Péter Törzsök; Tim Nestler; Matthaeus Majewski; Andreas Hiester; Tomas Buchler; Sonia Vallet; Hana Studentova; Sandra Schönburg; Dora Niedersüß-Beke; Julia Ring; Emanuela Trenti; Axel Heidenreich; Christian Wülfing; Hendrik Isbarn; Uwe Pichlmeier; Martin Pichler
Journal:  Ther Adv Med Oncol       Date:  2022-03-31       Impact factor: 8.168

Review 7.  Contemporary options and future perspectives: three examples highlighting the challenges in testicular cancer imaging.

Authors:  Gamal Anton Wakileh; Christian Ruf; Axel Heidenreich; Klaus-Peter Dieckmann; Catharina Lisson; Vikas Prasad; Christian Bolenz; Friedemann Zengerling
Journal:  World J Urol       Date:  2021-11-15       Impact factor: 4.226

8.  Associations of serum levels of microRNA-371a-3p (M371) with risk factors for progression in nonseminomatous testicular germ cell tumours clinical stage 1.

Authors:  Klaus-Peter Dieckmann; Cansu Dumlupinar; Arlo Radtke; Cord Matthies; Renate Pichler; Pia Paffenholz; Jörg Sommer; Alexander Winter; Friedemann Zengerling; Finja Hennig; Christian Wülfing; Gazanfer Belge
Journal:  World J Urol       Date:  2021-11-14       Impact factor: 4.226

Review 9.  [Diagnosis and treatment of Leydig cell tumors].

Authors:  Sabine Kliesch
Journal:  Urologe A       Date:  2021-07-05       Impact factor: 0.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.